Both T h 2 cells and group 2 innate lymphoid cells (ILC2s) contribute to allergic diseases. However, their exact role and relationship in nasal allergic disorders are unclear. In this study, we investigated the cooperation of T h 2 cells and ILC2s in a mouse model of nasal allergic disorder. To differentially activate T h 2 cells and/or ILC2s in nasal mucosa, mice were intra-nasally administered ovalbumin (OVA) antigen, papain, an ILC2-activator, or both for 2 weeks. Epithelial thickness and number of eosinophils in the nasal mucosa were evaluated at 24 h after the final challenge. Intra-nasal administration of OVA and papain preferentially activated T h 2 cells and ILC2s, respectively, in the nose. Both OVA and papain increased the nasal epithelial thickness and number of eosinophils, and their coadministration significantly enhanced the symptoms. Although T-/B-cell-deficient mice showed severely decreased nasal symptoms induced by OVA or OVA-plus-papain, the mice still showed slight papain-induced nasal symptoms. In ILC2-deficient mice, OVA-plus-papain-induced nasal symptoms were suppressed to the same level as OVA-alone. Similarly, IL-33-and ST2-deficient mice showed decreased OVA-plus-papain-induced nasal symptoms. IL-5 induced eosinophilia only, but IL-13 contributed to both nasal epithelial thickening and eosinophilia induced by OVA-pluspapain. Dexamethasone ameliorated OVA-alone-induced nasal epithelial thickening. However, OVAplus-papain-induced nasal epithelial thickening was only partially controlled by dexamethasone. These results demonstrate that IL-33/ST2-pathway-mediated ILC2 activation exacerbated T h 2-cellinduced nasal inflammation by producing IL-13. Although T h 2-cell-alone-induced nasal inflammation was controlled by corticosteroid treatment, the activation of ILC2s conferred treatment resistance. Therefore, ILC2s and their activators could be therapeutic targets for treatment-refractory nasal allergic disorders.
Introduction
Although type 2 immunity is essential for protection against parasite infection and against venoms, the aberrant activation of type 2 immunity to innocuous antigens elicits allergic diseases (1) . In the nose, allergic rhinitis (AR) and chronic rhinosinusitis with nasal polyps (CRSwNP) are the two major type 2 immunity-associated diseases. The symptoms of AR are characterized by early-phase responses (sneezing and watery runny nose) caused by IgE-mediated mast cell degranulation and late-phase responses (nasal congestion) caused by infiltrated inflammatory cells and tissue damage (2) (3) (4) . CRSwNP is a T h 2-dominated subtype of CRS characterized by the presence of nasal polyps and intensive eosinophil infiltration (5) . T h 2 cells play a central role in the pathogenesis of disease by producing type 2 cytokines such as IL-4, IL-5 and IL-13 (2) (3) (4) . IL-5 increases the migration, adhesion and survival of eosinophils, which promotes tissue eosinophilia. IL-13 also contributes to eosinophilia and promotes gobletcell and epithelial-cell hyperplasia (5) . In addition, type 2 cytokines reduce tissue plasminogen activator levels in nasal epithelial-cell, which promote fibrinogenesis, resulting in nasal polyp generation in CRSwNP (6) .
Group 2 innate lymphoid cells (ILC2s) were recently identified as a novel cell population that produces large amounts of type 2 cytokines in response to epithelium-derived IL-25, IL-33 and thymic stromal lymphopoietin (7) (8) (9) (10) . Lung inhalation of allergens such as papain, Alternaria alternata and house dust mite induces IL-33-dependent ILC2 activation resulting in the development of allergic pulmonary inflammation independent of adaptive immunity (11) (12) (13) . In addition, ILC2s promote the proliferation of T h 2 cells directly, which is cell-contact-and MHC-class-II-dependent (14) (15) (16) (17) and, indirectly, which is IL-13-mediated dendritic-cell-dependent (18) . Therefore, ILC2s contribute to the exacerbation of allergic pulmonary inflammation by producing type 2 cytokines and activating T h 2 cells.
ILC2s have also been implicated in nasal allergic diseases. Circulating ILC2s are increased in patients with seasonal AR during the allergen season (19, 20) and in patients with cat allergy after nasal provocation (21) . In addition, ILC2s were observed in nasal polyps from CRSwNP patients (22) (23) (24) (25) (26) . Therefore, ILC2s may have a role in promoting nasal type 2 inflammation. However, because of the lack of experimental studies focusing on nasal ILC2s, their exact role in nasal allergic diseases is poorly understood. Furthermore, the interrelationship between T h 2 cells and ILC2s in the nose has not been examined.
Here, we investigated whether T h 2 cells and ILC2s cooperate in nasal type 2 inflammation by using ovalbumin (OVA) and papain as a T h 2-cell-inducing antigen and an ILC2 activator, respectively. We revealed that the simultaneous activation of T h 2 cells and ILC2s in the nose additively exacerbated nasal epithelial thickening and eosinophilia. In addition, ILC2 activation mediated via the IL-33/ST2-pathway might confer corticosteroid resistance to nasal epithelial thickening.
Methods

Mice
BALB/c and C57BL/6 mice were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). BALB/cbackground Il33 −/− and Il1rl1 −/− mice were generated as previously described (27) (28) (29) . BALB/c-background Rag2 −/− mice were purchased from Taconic (Germantown, NY, USA). C57BL/6-background Rora sg/sg , ΔdblGATA and Il13 −/− mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). All mice were maintained under specific pathogen-free conditions. All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care Committee of the Hyogo College of Medicine (No. 14-007 and No. .
Mouse model
Mice were intra-nasally (i.n.) administered PBS (20 µl), 5% OVA (20 µl in PBS), papain (10 µg per 20 µL in PBS containing 2.5 mM l-cysteine) or OVA-plus-papain without alum on days 1, 3, 6, 8, 10 and 13. To examine the effect of A. alternata extract in nasal mucosa, mice were i.n. administered A. alternata extract (100 µg per 20 µl in PBS) together with OVA using the same time course as for the administration of OVA-plus-papain. At 24 h after the last challenge, mice were euthanized for analysis. To deplete eosinophils, anti-IL-5 antibody (100 µg per body) was intra-peritoneally (i.p.) administered on days 1, 5, 8 and 12. In some experiments, mice were i.p. administered dexamethasone (2.5 or 5 mg kg −1 ) at 24 and 2 h before each nasal challenge.
Bone marrow transplantation
Recipient 7-week-old C57BL/6 wild-type (WT) mice were lethally irradiated (11 Gy). Donor bone marrow (BM) cells were prepared from 3-to 4-week-old WT or Rora sg/sg mice. BM cells (10 7 cells per body) were suspended in 100 µl PBS and transferred intravenously into recipients. Mice were used for experiments from 8 weeks after transplantation.
Reagents
PE-conjugated antibodies against CD3 (145-2C11), CD8a (53-6.7) and FITC-conjugated antibody against CD90.2 (Thy1.2) (53-2.1) were purchased from eBioscience (San Diego, CA, USA). PE-conjugated antibodies against CD4 (RM4-5), CD49b (DX-5) and Siglec-F (E50-2440) were purchased from BD Biosciences (San Diego, CA, USA). PE-conjugated antibodies against CD11b (M1/70), CD11c (N418), CD19 (6D5), Ly-6G/Ly-6c (Gr-1) (RB6-8C5), IL-5 (TRFK5), allophycocyanin (APC)-conjugated streptavidin, and Pacific Blue-conjugated antibody against CD45 (30-F11) were purchased from BioLegend (San Diego, CA, USA). APC-conjugated antibody against IL-13 (eBio13A) and PE-conjugated antibody against IgE were purchased from eBioscience and Southern Biotech (Birmingham, AL, USA), respectively. Biotin-conjugated antibody against T1/ST2 (DJ8) was purchased from MD Bioproducts (St Paul, MN, USA). Papain from papaya latex, OVA (grade V) and l-cysteine were purchased from SigmaAldrich Japan (Tokyo, Japan). Dexamethasone was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). A. alternata extract was purchased from ITEA Inc. (Tokyo, Japan). The neutralizing monoclonal anti-IL-5 antibody was described previously (30) .
Measurement of papain-and OVA-specific IgG1
Serum was collected at days 0 and 14. Serum papain-specific IgG1 levels were measured by ELISA, as described previously (31) . Plates were coated with papain (10 µg ml −1 ) and blocked with PBS containing 1% BSA. The coated plates were incubated with serum (1/50 000 dilution) for overnight at 4°C. After that, the plates were incubated with biotin-conjugated goat anti-mouse IgG1 mAb (Southern Biotech) for 1.5 h at 37°C. HRP-conjugated streptavidin (R&D Systems, Inc., MN, USA) and TMB Microwell Peroxidase Substrate System (SeraCare Life Sciences, MA, USA) were used for detecting papain-specific IgG1. OVA-specific IgG1 levels were measured by Mouse OVA-IgG 1 ELISA KIT according to the manufacturer's direction (AKRIE-040, Shibayagi, Gunma, Japan).
Histological analysis
Nasal tissue specimens were generated as previously described (32) . Briefly, nasal tissues were fixed in 4% paraformaldehyde at 4°C for 3 days and decalcified in 0.12 mol l −1 EDTA solution (pH 7.4) for 7 days at room temperature. Tissues were embedded in paraffin, sectioned coronally (4-µm thickness), and then stained with H&E. To evaluate the nasal epithelial thickness, bilateral nasal mucosae on posterior lateral meatus were measured at unilateral three random points using cellSens imaging software and AX80/ DP72 (OLYMPUS, Tokyo, Japan), and the mean values of the mucosal thickness were calculated. To assess the eosinophil infiltration into nasal mucosa, eosinophils, which were stained with eosin and had two-lobed nuclei, were counted in bilateral nasal anterior lateral mucosae. For IL-33 staining in nasal tissue, deparaffinized sections were heated in citrated buffer (pH 6.0) for antigen retrieval. After blocking with 1% BSA in PBS for 1 h, sections were incubated with rabbit anti-mouse Biotinylated IL-33 antibody (R&D Systems), followed by streptavidin, Alexa Fluor 488 conjugate (Invitrogen, MA, USA). Stained sections were mounted with Prolong Antifade Gold with DAPI (Invitrogen) and evaluated under a microscope Zeiss LSM 780 (Carl Zeiss). Computer software, Zen 2012 (Carl Zeiss), was used for image processing and analysis.
Flow cytometry
To count the number of ILC2s in nasal mucosa, whole nasal cells were isolated as previously described (33) . Briefly, noses were minced and digested for 50 min at 37°C with collagenase (150 U ml −1 ) and DNase I (10 µg ml −1 ). Subsequently, cell suspensions were filtered using a cell strainer and red blood cells were lysed. ILC2s in nasal mucosa were stained with antibodies against CD45, lineage markers (CD3, CD4, CD8, CD11b, CD11c, CD19, DX-5, Gr-1, Siglec F and IgE), Thy1.2 and ST2. Intracellular cytokine staining was performed using BD Cytofix/Cytoperm™ Plus Fixation/permeabilization Kit (BD Biosciences). Stained cells were analyzed by a FACSCanto II flow cytometer (BD Biosciences) and FlowJo software (version 7.6.1, Tree Star Inc., Ashland, OR, USA). Lineage
+ cells were defined as nasal ILC2s (Fig. 1C) .
Stimulation of nasal cells in vitro for intracellular cytokine staining
Isolated whole nasal cells were stimulated with PMA (30 ng ml −1 , Sigma Aldrich) and ionomycin (A23187) (500 ng ml −1 , Sigma Aldrich) for 4 h in the presence of Golgi-Stop.
Quantitative RT-PCR
CD4
+ T cells in nasal mucosa were isolated by an Auto MACS Separator using anti-mouse-CD4 MicroBeads (L3T4) (Miltenyi Biotec, Bergisch Gladbach, Germany). Total RNAs from CD4 + T cells were isolated using an RNeasy Mini Kit (Qiagen, Hilden, Germany) and cDNA was synthesized using ReverTra Ace (Toyobo, Osaka, Japan). Gene expression levels were quantified using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) and the Thermal cycler dice RT-PCR system (Takara Bio Inc., Otsu, Japan).
The results are shown as the relative expression standardized to eukaryotic 18S rRNA levels. The specific primers and probes used for quantitative RT-PCR were TaqMan probes for Il4, Il5, Il13 and 18S rRNA (Applied Biosystems).
Statistical analysis
Representative data or pooled data were presented as the means ± SEMs of more than two independent experiments. Two-tailed Student t-test and one-way ANOVA with Tukey test were used to determine the statistical significance between two groups and between more than two groups, respectively. P values of <0.05 were considered significant.
Results
Nasal administration of OVA and papain activates T h 2 cells and ILC2s, respectively, to cooperatively elicit nasal type 2 inflammation
To investigate the contribution of T h 2 cells and ILC2s in nasal allergy, we used a model antigen OVA and a well-characterized ILC2-activator, papain, which activates ILC2s through the IL-33/ST2-pathway (13, 31) and is a cause of occupational rhinoconjunctivitis (34, 35) . As shown in Fig Because papain is also an antigen with adjuvant activity (37), we used a low dose of papain (10 µg per dose) to minimize the effect on T h 2 cell activation. In this protocol, papain significantly expanded the nasal ILC2 population (Fig. 1D) . Although papain induced papain-specific IgG1 production (Fig. 1E) , papain addition to OVA administration did not enhance OVAspecific IgG1 production ( Fig. 1F) and OVA-induced nasal T h 2 cell activation (Fig. 1B) . OVA-plus-papain administration activated both T h 2 cells and ILC2s in noses (Fig. 1B and D) . Therefore, the nasal administration of OVA or papain preferentially activated T h 2 cells or ILC2s, respectively.
Activation of type 2 immunity in noses induced nasal mucosal hyperplasia and eosinophilia that resulted in nasal congestion in AR and polyp generation in CRS (3, 5) . We examined the effect of the activation of T h 2 cells and/or ILC2s on nasal epithelial thickness in the posterior lateral meatus and on nasal eosinophilia. Both OVA-and papain-alone administration induced nasal epithelial thickening ( Fig. 2A and B) and eosinophilia (Fig. 2C) , and coadministration of OVA together with papain induced significantly stronger nasal type 2 inflammation compared with OVA-or papainalone. In addition, another ILC2-activator A. alternata extract, an environmental fungus that may cause CRS (38) , also exacerbated OVA-induced nasal epithelial thickening (Fig. 2D) . These results suggest that the simultaneous activation of T h 2 cells and ILC2s in noses additively exacerbates nasal type 2 inflammation. Fig. 1(A) . (E, F) Mouse sera were collected at days 0 and 14. Serum papain-specific (E) and OVA-specific IgG1 (F) were measured by ELISA. Data are mean ± SEM. n = 5 (B and D); n = 4 (E and F). *P < 0.05, **P < 0.01. N.S., not significant.
T h 2 cells and ILC2s contribute in parallel to OVA-pluspapain-induced nasal type 2 inflammation
Papain did not enhance OVA-induced nasal CD4 + T-cell activation or OVA-specific IgG1 production. However, because papain administration induced papain-specific IgG1, papain-induced T h 2 cells, rather than papain-induced ILC2s, might contribute to the exacerbation of nasal symptoms. To directly examine whether ILC2s contribute to papain-induced exacerbation of nasal type 2 inflammation, we used T-and B-cell-deficient mice (Rag2 −/− mice) and ILC2-deficient mice [Rora sg/sg → WT BM transplantation (WT BMT) mice]. In Rag2 −/− mice, nasal epithelial thickening and eosinophilia induced by OVA-alone administration were completely abrogated ( Fig. 3A and B) . OVA-plus-papain-administration-induced nasal epithelial thickening and eosinophilia were also largely attenuated in Rag2 −/− mice ( Fig. 3A and B) , indicating the essential role of T h 2 cells in this model. Rag2 −/− mice, however, showed a slight increase in nasal epithelial thickness Fig. 2(B) . Each dot represents an individual mouse and the bars indicate mean ± SEM of each group. n = 10-11 (B); n = 6 (C); n = 5 (D). *P < 0.05, **P < 0.01.
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and number of eosinophils by OVA-plus-papain administration indicating that activation of ILC2 alone can induce nasal symptoms even though relatively weakly. The Rora sg/sg → WT BMT system has been well defined as ILC2 deficient with normal numbers of T h 2 cells. Papain-induced ILC2s were completely depleted in the nasal mucosa of Rora sg/sg → WT BMT ; n = 5 (C-E); n = 2-4 (F). *P < 0.05, **P < 0.01. mice (Fig. 3C) . Although OVA-alone-induced nasal epithelial thickening and eosinophilia were comparable between WT → WT and Rora sg/sg → WT BMT mice, the papain-induced exacerbation of nasal thickening and eosinophilia was suppressed to levels comparable with OVA-alone in Rora sg/sg → WT BMT mice ( Fig. 3D and E) . Because ILC2s can affect T h 2 cell priming or activation in the lungs (14-18), we investigated whether depletion of ILC2s influenced T h 2 cell responses. mRNA levels of Il4, Il5 and Il13 in nasal CD4 + T cells in OVAplus-papain-administered Rora sg/sg → WT BMT mice were not decreased, but rather increased, compared with those in OVA-plus-papain-administered WT → WT BMT mice (Fig. 3F) . These results suggested that the papain-induced exacerbation of nasal type 2 inflammation was mediated by the direct additive effect of ILC2 activation, but not through the augmentation of T h 2 cell responses. Therefore, papaininduced ILC2s and OVA-induced T h 2 cells cooperate in parallel to induce nasal allergic symptoms.
IL-33/ST2-signaling contributes to the ILC2-mediated exacerbation of nasal type 2 inflammation
The IL-33/ST2-signaling pathway is essential for papaininduced ILC2 activation (13, 31) . First, to examine whether papain promotes IL-33 secretion from nasal epithelial cells, we performed immunohistochemistry for IL-33 in nasal mucosa. Mice were administrated PBS, OVA or OVA-plus-papain as in Fig. 1(A) , and IL-33 expression in the nasal mucosa was evaluated before and after the final nasal challenge. Before the final challenge, nasal IL-33 levels were higher in OVAplus-papain-administered mice compared with PBS-and OVA-administrated mice. Nasal IL-33 levels were decreased at 1 h, and partially recovered by 24 h after OVA-plus-papain administration (Fig. 4A) . However, PBS-or OVA-alone administration did not affect nasal IL-33 levels. Of note, IL-33 was not detected in OVA-plus-papain-administered Il33 −/− mice. These results suggested that papain induced temporal IL-33 secretion from nasal epithelial cells, and chronic nasal exposure to papain enhanced tissue IL-33 levels. Next, to investigate the contribution of IL-33/ST2-signaling in OVAplus-papain-induced nasal type 2 inflammation, we used Il33 −/− and Il1rl1 −/− (ST2 deficient) mice. OVA-plus-papaininduced nasal epithelial thickening and eosinophilia were significantly abrogated in Il33 −/− mice and the levels were comparable to OVA-alone-administered mice, while OVAalone-induced epithelial thickening and eosinophilia were comparable between WT and Il33 −/− mice ( Fig. 4B and C) . Similarly, nasal epithelial thickening and eosinophilia were not exacerbated by papain in Il1rl1 −/− mice and were comparable between OVA-plus-papain-and OVA-alone-administered Il1rl1 −/− mice ( Fig. 4D and E) . To investigate whether IL-33/ ST2-signaling is important for the activation of nasal T h 2 cells and/or ILC2s, we examined the expression of Il4, Il5 and Il13 mRNA levels in CD4 + T cells and the number of IL-5/ IL-13-producing ILC2s in the nose. Il4, Il5 and Il13 levels in CD4 + T cells were comparable between OVA-or OVA-pluspapain-administrated WT and Il33 −/− mice (Fig. 4F) , while the number of IL-5/IL-13-producing ILC2s in OVA-plus-papainadministrated Il33 −/− mice was significantly lower than that in WT mice (Fig. 4G ). These results demonstrate that IL-33/ ST2-signaling contributes to the ILC2-mediated exacerbation of nasal type 2 inflammation. However, IL-33/ST2-signaling has little contribution to T h 2 cell activation in this OVA-and papain-induced nasal allergy model.
Nasal eosinophilia is dispensable for nasal epithelial thickening
Because eosinophils might be involved in epithelial thickening and tissue remodeling in allergic pulmonary inflammation by producing proteases (39-42), we depleted eosinophils in WT mice by the i.p. administration of anti-IL-5 antibody. OVAalone-and OVA-plus-papain-induced nasal epithelial thickening were not suppressed by anti-IL-5 antibody, although numbers of nasal eosinophils were markedly reduced ( Fig. 5A and B) . In addition, nasal epithelial thickening was not ameliorated in OVA-alone and OVA-plus-papain-treated eosinophil-deficient ΔdblGATA mice (Fig. 5C) . Therefore, even though T h 2 cells and ILC2s induce strong nasal eosinophilia by producing IL-5, eosinophils are not a major contributor to OVA-and papain-induced nasal epithelial thickening.
IL-13 is responsible for ILC2-mediated exacerbation of nasal type 2 inflammation
IL-13 induces eosinophil accumulation, epithelial thickening and mucous cell hyperplasia in lungs (43) . To examine the effect of IL-13 in OVA-and papain-induced nasal type 2 inflammation, Il13 −/− mice were i.n. administered OVA-alone or OVA-plus-papain. Papain-induced exacerbation of nasal type 2 inflammation was abrogated in Il13 −/− mice as OVAalone and OVA-plus-papain administration induced comparable levels of nasal epithelial thickening and eosinophilia ( Fig. 6A and B) . However, OVA-alone-induced epithelial thickening and eosinophilia were not ameliorated in Il13 −/− mice ( Fig. 6A and B) . Therefore, IL-13 derived from ILC2s, but not from T h 2 cells, contributes to papain-induced exacerbation of nasal epithelial thickening and eosinophilia.
Exacerbated nasal epithelial thickening by papain is refractory to corticosteroid treatment
ILC2s and IL-33 are assumed to mediate corticosteroid treatment resistance in nasal (44) and lung allergic responses (45) . To investigate whether papain-induced ILC2 activation confers corticosteroid resistance in nasal allergy, OVA-or OVA-pluspapain-administered mice were i.p. injected with dexamethasone (2.5 or 5 mg kg −1 ) at 24 and 2 h before each nasal challenge. OVA-induced nasal epithelial thickening was suppressed by dexamethasone in a dose-dependent manner and high-dose dexamethasone administration almost completely ameliorated the symptoms (Fig. 7A) . Even though low-dose dexamethasone suppressed nasal epithelial thickening in OVA-plus-papain-administered mice with a similar efficacy to that in OVA-alone-administered mice, high-dose dexamethasone did not have a greater suppressive effect and the symptoms remained in the OVA-plus-papain-administered group (Fig. 7A) . Because the IL-33/ST2-pathway mediates papaininduced ILC2 activation (Fig. 4) , the nasal epithelial thickness in OVA-plus-papain-administered Il1rl1 −/− mice treated with high-dose dexamethasone was comparable to that of the PBSadministered groups (Fig. 7B) . Nasal eosinophilia induced by OVA-alone or OVA-plus-papain was similarly suppressed by ; n = 3-4 (C); n = 6-7 (D); n = 5-6 (E); n = 4-5 (F, G). *P < 0.05, **P < 0.01. N.S., not significant. dexamethasone and was dose-dependent (Fig. 7C) . Thus, although nasal eosinophilia was well controlled by corticosteroids regardless of the initial cause, papain-exacerbated nasal epithelial thickening was corticosteroid resistant. High-dose dexamethasone completely suppressed OVA-plus-papaininduced expression of Il4, Il5 and Il13 in CD4 + T cells (Fig. 7D) . Although dexamethasone decreased the number of IL-5/IL-13-producing ILC2s even in PBS-administered mice (Fig. 7E) , the percentage of IL-5/IL-13-producing ILC2s in OVA-plus-papainadministered mice was not decreased by dexamethasone (Fig. 7F) . Taken together, these results suggest that nasal ILC2 activation via the IL-33/ST2-pathway induces corticosteroidresistant nasal type 2 inflammation.
Discussion
In this study, we demonstrated that nasal ILC2s additively exacerbated T h 2-cell-induced nasal type 2 inflammation in mice. Interestingly, IL-13 induced by ILC2s, but not T h 2 cells, was critical for the exacerbation of nasal allergic symptoms. Furthermore, ILC2s activated by the IL-33/ST2-pathway conferred corticosteroid resistance.
Although T h 2 cells have a central role in allergic diseases by secreting type 2 cytokines, ILC2s may also be an important innate source of cytokines (1, 7) . To investigate the cooperation between T h 2 cells and ILC2s in nasal allergy, we generated a mouse model allowing the simultaneous activation of T h 2 cells and ILC2s in the nasal mucosa. We successfully induced the selective activation of nasal T h 2 cells and ILC2s by using OVA and low-dose papain, respectively. Using this mouse model, we demonstrated that the activation of ILC2s additively enhanced T h 2-cell-induced nasal type 2 inflammation during the early chronic stage of disease. In the lungs, ILC2s induce type 2 immunity by inducing T h 2 cell priming and/or activation (14) (15) (16) (17) (18) . In the nose, however, ILC2s and T h 2 cells are independently activated by different stimuli and contribute in parallel to nasal type 2 inflammation. (A, B) ; n = 6-7 (C). *P < 0.05, **P < 0.01. N.S., not significant. IL-13 can be produced from several cell types other than T h 2 cells and ILC2s including mast cells, basophils, eosinophils and NKT cells. However, the data from Rag2 −/− mice, which lack NKT cells, and ΔdblGATA mice, which lack eosinophils, exclude the involvement of NKT cells and eosinophils in papain-induced IL-13 essential for augmented nasal symptoms. In addition, papain did not enhance OVA-induced upregulation of mast-cell-and basophil-specific genes in the nose (data not shown). Therefore, ILC2s may be the major cell population for IL-13 production in response to papain in our model.
Currently, it is believed that ILC2s are associated with the development of nasal polyps in CRSwNP because the presence of ILC2s in nasal polyps in CRSwNP patients was reported by several groups (22) (23) (24) (25) (26) . However, this is controversial for cases of AR. A study reported a comparable number of ILC2s in PBMCs from AR patients and healthy controls (46) , whereas circulating ILC2s were increased in patients with seasonal AR during the allergen season (19, 20) and in patients with cat allergy immediately after nasal provocation (21) . In the present study, we showed that the i.n. administration of IL-33 inducers, such as papain and A. alternata extract, increased the number of ILC2s in the nasal mucosa, but that the administration of OVA, a T-cell activating antigen, did not. Thus, we hypothesized that ILC2s activated in nasal allergic disorders are associated with the affected allergens or microbes. When allergens that induce IL-33 production by nasal epithelial cells are inhaled, ILC2s are activated in the nasal mucosa and the symptoms of AR may be exacerbated or polyp generation might be induced in CRS. Indeed, a study demonstrated that the number of circulating ILC2s in AR patients was different depending on the specific sensitizing allergens (19-21, 46, 47) .
The development of anti-type 2 cytokine therapies for the treatment of allergic disorders is currently being investigated (48, 49) . Anti-IL-5 antibody (mepolizumab) significantly reduced nasal polyp size and improved computational tomography scores in CRSwNP, while some symptoms of CRS such as nasal congestion and rhinorrhea were not improved by the treatment (50) . Our current study also demonstrated that anti-IL-5 antibody treatment did not suppress OVA-alone-and OVA-plus-papain-induced nasal epithelial thickening, despite a significant reduction in nasal eosinophilia. In contrast, both nasal epithelial thickening and nasal eosinophilia induced by OVA-plus-papain administration were significantly suppressed in Il13 −/− mice. Therefore, IL-13 might be a better therapeutic target for the treatment of nasal allergic diseases. However, OVA-alone-induced nasal epithelial thickening was not suppressed in Il13 −/− mice, suggesting that T h 2 cells produce other factor(s) that mediate nasal type 2 inflammation. IL-4 might be such a factor, because it signals through both IL-4 and IL-13 receptors and contributes to epithelial thickening (51) . Human monoclonal antibody against the IL-4 receptor α subunit (dupilumab), which inhibits the effects of both IL-4 and IL-13, significantly improved nasal polyp scores and nasal symptoms, including nasal congestion and rhinorrhea, in patients with CRS and nasal polyposis refractory to intra-nasal corticosteroids (52) . Thus, it will be interesting to investigate whether the T h 2-cell-derived factor that mediated OVA-induced nasal epithelial thickening in the current study was IL-4.
Corticosteroid treatment resistance is a significant clinical problem in CRSwNP and asthma. IL-33 administration conferred ILC2-dependent corticosteroid resistance in an OVA-induced allergic pulmonary inflammation model (45) . In addition, increased levels of nasal Il33 levels were associated with corticosteroid-resistant CRSwNP (44) . The present study indicated that exacerbated nasal epithelial thickening induced by papain administration was dexamethasone treatment resistant. Because papain induced the IL-33/ ST2-pathway-dependent activation of ILC2s, and OVA-pluspapain-induced nasal epithelial thickening was controlled in dexamethasone-treated ST2-deficient mice, ILC2 activation may confer corticosteroid resistance during nasal type 2 inflammation. Thus, the regulation of ILC2 activation or IL-33 production might control refractory and recurrent nasal polyps in CRSwNP.
In summary, we identified a relationship between T h 2 cells and ILC2s in nasal type 2 inflammation, whereby 
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ILC2s additively exacerbate T h 2-dependent nasal inflammation. ILC2-derived IL-13 might play a potent role in the exacerbation of nasal allergic symptoms. Furthermore, ILC2s contributed to corticosteroid treatment resistance in nasal type 2 inflammation. Therefore, ILC2s and the ILC2 activator, IL-33, might be promising therapeutic targets for the treatment of refractory nasal allergic disorders. Further studies specifically focusing on nasal ILC2s and T h 2 cells are required to fully determine the underlying pathological mechanisms in refractory nasal allergic disorders.
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